Other languages Torii Pharmaceutical Co., Ltd.

Equities

4551

JP3635800000

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-07-12 am EDT			5-day change	1st Jan Change
3,815 ^JPY	+2.28%		+2.14%	+7.31%

May. 15	Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth	MT
May. 15	Verrica Pharmaceuticals Inc. Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study Ycanth for the Treatment of Common Warts	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth	May. 15
Verrica Pharmaceuticals Inc. Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study Ycanth for the Treatment of Common Warts	May. 15
LIM Advisors Partially Withdraws Shareholder Proposal	Feb. 12
Torii Pharmaceuticals Opposes Shareholder Proposal	Feb. 08
Verrica Pharmaceuticals' Partner Reports Positive Data From Phase 3 Trial of Skin Infection Treatment	Dec. 15
Torii Pharmaceutical Co., Ltd. Announces Positive Top-Line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan	Dec. 15
ALK Abello Adds Grass Pollen Allergy Drug to Torii License Deal in Japan	Dec. 12
ALK-Abelló A/S Expands Partnership with Torii Pharmaceutical Co., Ltd. in Japan	Dec. 12
BioCryst Amends Deal With Torii Pharmaceutical for Orladeyo's Commercialization in Japan; Shares Rise	Nov. 30
LIM Advisors Submits Shareholder Proposal to Torii Pharmaceutials	23-02-10
Japan Tobacco urged to sell drug unit by activist shareholder LIM	23-01-20
Verrica Pharmaceuticals Receives $8 Million Milestone Payment From Torii Pharmaceutical After Phase 3 Viral Skin Disease Trial Gets Underway	22-08-01
Torii Pharmaceutical Co., Ltd. Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum	22-08-01
Effissimo Capital Management Submits Shareholder Proposal to Torii Pharmaceutical	21-08-06
BioCryst Pharmaceuticals' : Orladeyo Receives Approval for Japanese NHI Price Listing	21-04-14
Akebia Therapeutics : Obtains Approval For Additional Indication of Riona Tablets in Japan	21-03-24
Verrica Pharmaceuticals : Torii Strike Exclusive Licensing Deal To Develop, Commercialize VP-102 For Molluscum, Common Warts in Japan	21-03-17
Torii Pharmaceutical Co., Ltd. Revises Earnings Guidance for the Fiscal Year Ended December 31, 2019	20-01-20
Japan Tobacco Inc. Revises Earnings Guidance for Fiscal Year Ended December 31, 2019	19-10-31
Japan Tobacco: la rentabilité s'essouffle au 2e trimestre, minée par les changes	19-07-31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Torii Pharmaceutical Co., Ltd.

Equities

4551

JP3635800000

Other languages

Filters